European multicenter trials of curosurf for treatment of neonatal respiratory distress syndrome.

Abstract

Curosurf, a preparation of polar lipids and hydrophobic proteins isolated from porcine lungs by liquid-gel chromatography, is currently used in European multicenter trials for prevention and treatment of neonatal respiratory distress syndrome (RDS). In babies requiring artificial ventilation with 60-100% oxygen, tracheal instillation of a single dose of Curosurf (200 mg/kg) leads to a dramatic improvement of gas exchange and reduced mortality, without increasing the incidence of neurodevelopmental handicap among survivors. Several factors, including high ventilator pressure and oxygen requirements, have a negative impact on the therapeutic response, suggesting that the patients should be treated at a comparatively early stage of the disease. Clinical trials testing this hypothesis, as well as the effect of multiple treatment doses, are in progress.

• Authors: B Robertson
• Journal: Lung (Lung) Vol. 168 Suppl Pg. 860-3 ( 1990) ISSN: 0341-2040 [Print] United States
• PMID: 2117204 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Pulmonary Surfactants

Topics

• Europe
• Follow-Up Studies
• Humans
• Infant
• Infant, Newborn
• Multicenter Studies as Topic
• Pulmonary Surfactants (administration & dosage)
• Randomized Controlled Trials as Topic
• Respiratory Distress Syndrome, Newborn (therapy)